• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

FDA Drug Shortages

  • Print
  • Share
  • E-mail
-

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

 Dihydroergotamine Mesylate Injection

 Status: Currently in Shortage

 » Date first reported: 08/06/2014
 » Therapeutic Categories: Neurology

Paddock Laboratories, LLC (Revised 11/04/2014)

Company Contact Information:
866-634-9120

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
1 mg/mL ampoule, 10s (NDC 0574-0850-10) Unavailable. Product has been manufactured and will be made available as it is released. Estimated shortage duration 1 month. Temporary interruption of supply. Requirements related to complying with good manufacturing practices.
1 mg/mL, 1 mL ampoule, 5s (NDC 0574-0850-05) Product is available and being shipped to customers. Temporary interruption of supply. Requirements related to complying with good manufacturing practices.

Valeant Pharmaceuticals North America LLC (New 08/12/2014)

Company Contact Information:
Customer Support:(800) 321-4576; Fax: (908) 927-1926; Medical Information/Product Complaints/Adverse Events:(877) 361-2719; Patient Assistance for Valeant Products: (866) 268-7325

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
D.H.E. 45 (DIHYDROERGOTAMINE MESYLATE) Injection 1 mg/mL (NDC 68682-357-10) 1 month Not available. Requirements related to complying with good manufacturing practices.
-
-